title: Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.
authors.forename: Melody C
authors.initials: MC
authors.lastname: Carter
authors.forename: Jamie A
authors.initials: JA
authors.lastname: Robyn
authors.forename: Peter B
authors.initials: PB
authors.lastname: Bressler
authors.forename: John C
authors.initials: JC
authors.lastname: Walker
authors.forename: Gail G
authors.initials: GG
authors.lastname: Shapiro
authors.forename: Dean D
authors.initials: DD
authors.lastname: Metcalfe
mesh_terms: D000293:Adolescent; D000707:Anaphylaxis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D008297:Male; D034721:Mastocytosis, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D000069444:Omalizumab; D017455:Receptors, IgE / Q000037:antagonists & inhibitors; D014582:Urticaria Pigmentosa / Q000188:drug therapy / Q000276:immunology / Q000473:pathology
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017455:Receptors, IgE; D000069444:Omalizumab